Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin PK in Severe Hepatic Impairment
NCT03818672Phase 4Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rifaximin in hepatic encephalopathy (HE), sponsored by Valeant Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at 7 days, Time of Maximum Concentration at 7 days and 1 more. Started Jan 2019; status: terminated.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT03818672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818672.